We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Ventana Paves the Way for High-Standard Companion Diagnostic Clinical Trials Services in China

By LabMedica International staff writers
Posted on 12 Aug 2014
Print article
Image: Exploratory testing at the Ventana CAP/CLIA laboratory at Quintiles China – a collaboration agreement to bring high-standard companion diagnostic clinical trials services in China (Photo courtesy of Ventana Medical Systems and PRNewsFoto).
Image: Exploratory testing at the Ventana CAP/CLIA laboratory at Quintiles China – a collaboration agreement to bring high-standard companion diagnostic clinical trials services in China (Photo courtesy of Ventana Medical Systems and PRNewsFoto).
Ventana Medical Systems, Inc. (Tucson, AZ, USA), member of the Roche Group, has announced a new agreement with Quintiles, Inc. (Durham, NC, USA) to offer College of American Pathology (CAP)-standard companion diagnostic testing services to cancer patients in China via early phase clinical trials conducted by pharmaceutical and biotech companies. This is good news for patients as China is one of the only countries in the world that requires all patient samples be tested in China, even those used in clinical trials. And incorporating a companion diagnostic strategy into a drug development program is more likely to help develop more effective drugs with improved safety profiles for patients.

"Our new relationship with Quintiles to offer companion diagnostic testing services in China moves our mission, to improve the lives of all patients afflicted with cancer, a big step forward," said Doug Ward, vice president and Companion Diagnostics Lifecycle leader, Ventana, "Our oncology pharma collaborators can now reach a large and growing number of patients that can benefit from clinical trial participation using targeted treatments and tests."

According to the World Health Organization (WHO)'s latest World Cancer Report, in 2012 China had the highest rate of new cancer cases recorded globally, 3.07 million (21.9%), and the trend is increasing, particularly in lung, liver, esophageal, and stomach cancers. This underscores the growing need for patients in China to have in-country access to the most advanced tissue diagnostic testing and companion therapeutics in the industry, which starts with early phase clinical trials.

"It's been extremely important to Ventana that we find a strategic laboratory in China that will help us uphold the CAP testing standard of excellence set by our global companion diagnostic CAP/CLIA laboratory in Tucson, Arizona, USA," said Dr. H. James Hnatyszyn, Ventana director of Laboratory Operations for companion diagnostics, "Quintiles has the experience, infrastructure, and qualified personnel to meet this challenge."

Early phase clinical trial testing according to the rigorous CAP standards set by Ventana is now available.

Related Links:
Ventana Medical Systems
Quintiles


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.